Clinical Trials Browser

Not yet recruiting × pembrolizumab × Thoracic × Clear all

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07431827 2026-02-25

KANDLELIT-013

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07361510 2026-02-19

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07360743 2026-02-10

META-1

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04266730 2026-01-28

PANDA-VAC

Phase 1 Not yet recruiting

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Squamous NSCLC

NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Not yet recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06951399 2025-07-22

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Phase 1 Not yet recruiting

Advanced Non-small Cell Lung Cancer

NCT06706219 2024-12-10

Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06572722 2024-08-27

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Phase 2 Not yet recruiting

Lung Neoplasms

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Phase 2 Not yet recruiting

Non-small Cell Lung Cancer Metastatic

NCT05425576 2024-03-15

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Phase 2 Not yet recruiting

Advanced Non-squamous Non-small-cell Lung Cancer

NCT04153734 2019-11-06

Evolution

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung